Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Earn FY2026 Earnings of $2.81 Per Share

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at Wedbush upped their FY2026 earnings per share estimates for Travere Therapeutics in a research note issued on Wednesday, October 9th. Wedbush analyst L. Chico now anticipates that the company will earn $2.81 per share for the year, up from their prior estimate of $2.28. Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.95) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2027 earnings at $3.83 EPS and FY2028 earnings at $3.92 EPS.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. The company had revenue of $54.12 million during the quarter, compared to analysts’ expectations of $49.50 million.

Other equities research analysts have also recently issued reports about the company. Leerink Partners reissued an “outperform” rating and issued a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday. Piper Sandler increased their price objective on Travere Therapeutics from $11.00 to $12.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. HC Wainwright dropped their price objective on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Bank of America increased their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Barclays increased their price objective on Travere Therapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.75.

Travere Therapeutics Trading Down 4.1 %

NASDAQ TVTX opened at $16.41 on Friday. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $18.60. The stock has a market cap of $1.26 billion, a P/E ratio of -8.73 and a beta of 0.73. The stock’s fifty day moving average price is $11.78 and its 200-day moving average price is $8.96. The company has a current ratio of 3.04, a quick ratio of 2.99 and a debt-to-equity ratio of 24.96.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TVTX. EntryPoint Capital LLC bought a new position in shares of Travere Therapeutics in the first quarter worth about $32,000. CWM LLC raised its stake in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the period. DRW Securities LLC bought a new position in shares of Travere Therapeutics in the second quarter worth about $95,000. Forefront Analytics LLC raised its stake in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after buying an additional 1,237 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Travere Therapeutics by 68.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock worth $113,000 after buying an additional 5,962 shares during the period.

Insiders Place Their Bets

In other Travere Therapeutics news, CEO Eric M. Dube sold 21,125 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the transaction, the chief executive officer now directly owns 361,975 shares of the company’s stock, valued at approximately $4,169,952. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Jula Inrig sold 2,191 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $25,240.32. Following the transaction, the insider now owns 62,633 shares of the company’s stock, valued at $721,532.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric M. Dube sold 21,125 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the completion of the transaction, the chief executive officer now directly owns 361,975 shares in the company, valued at $4,169,952. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,707 shares of company stock valued at $1,504,312. Insiders own 3.75% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.